Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe First Affiliated Hospital of Xiamen University

About this trial

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

Eligibility criteria

Qualifiers

Age ≥18

Relapsed and refractory patients with acute myeloid leukemia via morphology and immunology

ECOG:0-2

Life expectancy ≥ 3 months

Disqualifiers

Diagnosis of acute promyelocytic leukemia (APL)

Central nervous system leukemia

Bradycardia of less than 50 beats per minute, unless the subject has a pacemaker; Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);

Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg; History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);

Trial design

Treatments tested in this trial

  • venetoclax combining chidamide and azacitidine (VCA)

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators

The First Affiliated Hospital of Xiamen University

Lead sponsor

Fujian Provincial Hospital

Collaborator

Fujian Cancer Hospital

Collaborator

Zhangzhou manicipal hospital of Fujian Province

Collaborator

Jieyang People's Hospital

Collaborator

Dongguan People's Hospital

Collaborator

Huizhou Municipal Central Hospital

Collaborator